1. Home
  2. WERN vs NTLA Comparison

WERN vs NTLA Comparison

Compare WERN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werner Enterprises Inc.

WERN

Werner Enterprises Inc.

HOLD

Current Price

$28.59

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.38

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WERN
NTLA
Founded
1956
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
WERN
NTLA
Price
$28.59
$12.38
Analyst Decision
Hold
Buy
Analyst Count
14
20
Target Price
$31.21
$20.45
AVG Volume (30 Days)
944.3K
3.9M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
1.94%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
$2,974,396,000.00
$67,671,000.00
Revenue This Year
$21.44
N/A
Revenue Next Year
$6.87
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.92
52 Week Low
$23.02
$5.90
52 Week High
$38.45
$28.24

Technical Indicators

Market Signals
Indicator
WERN
NTLA
Relative Strength Index (RSI) 39.55 42.93
Support Level $26.64 $11.63
Resistance Level $29.62 $14.61
Average True Range (ATR) 1.04 0.68
MACD 0.13 -0.10
Stochastic Oscillator 34.90 4.20

Price Performance

Historical Comparison
WERN
NTLA

About WERN Werner Enterprises Inc.

Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: